- Home
- CEV vs NSPR Comparison
CEV vs NSPR Comparison
Compare CEV & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- NSPR
- Stock Information
- Founded
- CEV 1999
- NSPR 2005
- Country
- CEV United States
- NSPR United States
- Employees
- CEV N/A
- NSPR N/A
- Industry
- CEV Finance/Investors Services
- NSPR Medical/Dental Instruments
- Sector
- CEV Finance
- NSPR Health Care
- Exchange
- CEV Nasdaq
- NSPR Nasdaq
- Market Cap
- CEV 67.8M
- NSPR 79.7M
- IPO Year
- CEV N/A
- NSPR N/A
- Fundamental
- Price
- CEV $9.81
- NSPR $2.56
- Analyst Decision
- CEV
- NSPR Strong Buy
- Analyst Count
- CEV 0
- NSPR 2
- Target Price
- CEV N/A
- NSPR $4.75
- AVG Volume (30 Days)
- CEV 19.6K
- NSPR 48.4K
- Earning Date
- CEV 01-01-0001
- NSPR 05-09-2025
- Dividend Yield
- CEV 4.23%
- NSPR N/A
- EPS Growth
- CEV N/A
- NSPR N/A
- EPS
- CEV 0.36
- NSPR N/A
- Revenue
- CEV N/A
- NSPR $7,027,000.00
- Revenue This Year
- CEV N/A
- NSPR $28.93
- Revenue Next Year
- CEV N/A
- NSPR $172.18
- P/E Ratio
- CEV $29.36
- NSPR N/A
- Revenue Growth
- CEV N/A
- NSPR 8.49
- 52 Week Low
- CEV $8.83
- NSPR $2.07
- 52 Week High
- CEV $10.91
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- CEV 51.91
- NSPR 49.83
- Support Level
- CEV $9.74
- NSPR $2.40
- Resistance Level
- CEV $9.86
- NSPR $2.79
- Average True Range (ATR)
- CEV 0.08
- NSPR 0.16
- MACD
- CEV 0.03
- NSPR 0.02
- Stochastic Oscillator
- CEV 81.58
- NSPR 60.42
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.